clinical you validation We Thanks, last value a we we in TRiM clinical into that substantial thank of and these initiated Together, studies JNJ-XXXX Vince. platform TRiM Good XXX, of promising represent lot as TRiM the afternoon, predicted joining what with AMG over believe year, for we that everyone, and Early as our now ARO-LPA. progress clinic made build ARO-AAT. initiated the and That platform. XXXX, and to the pass. us drugs. to for clinical moving see X studies we first proofs-of-concept came ARO-HBV, for us, years to Amgen today. same be with We drive formerly clinical future
of the sought by shareholder development potentially into to accomplish in X XXXX. could build continuing We programs We introducing cardiometabolic value powerful clinic and we even thought more existing candidates. drug
our Phase continued these AMG JNJ-XXXX XXXX, X with potentially X We with Phase with were for accomplished. their a goals and launched Janssen XXX. II/III As study large studies Amgen with ARO-AAT. study II launched pivotal
Phase launching productive Association but have pipeline drug industry, November. in Sessions studies expanded from company Scientific I/IIa at we ARO-APOCX reported Importantly, we would ARO-ANGX, studies we finished. a cardiometabolic Heart data our for American were by and also these our represented the This clinical in very any candidates, and for initial year not
drug ever and target, first ARO-HSD. to our first tumor-targeted the candidate begin anticipated ARO-HIFX studies filed candidate against NASH the highly also clinical We for
is story What So productive this value we growth XXXX? how drivers. value think the of for We broad up do X creation? keep
address unmet raft a of medical the First, RNAi XXXX is new needs. the outside year to bringing of liver
by I in in tumors lung the to proof-of-concept the clinical target silence leaders clear We are and endeavor, year. we have solid believe and genes this end will of
and hepatocytes, pipeline in could done same have we new powerful of in what expanding value lung model offer we cell solid we can of options promise continued enabled believe rapidly This in growth. new our tumors. the do countless and at patients the types and look Just for
the advance X By liver-targeted in Second, cell skeletal to are to year, drug mean candidates potentially and business could studies the the cell a important X late-stage lot continue types have will up to pivotal studies. we to able XX could mid- It the programs to access TRiM clinical in the into be expect these looking to if pivotal wholly-owned, type, in clinic, to And up including our execute potentially we to we end up of muscle. were and reach multiple we targeting enable of third, different with an which expand trials. areas. to new TRiM-enabled of candidates X X platform
a Let this anywhere with all sink of I single, numbers platform. moment. a a for size those type there And believe is on company in don't remember that scalable is our this built reach.
risk rare as the key high-prevalence Arrowhead spread to couple diseases. gives a started. populations healthy of are could just getting clinical our believe know, and I and pipeline address however, out as candidates mix first, both across diversification later-stage provides XX, years This a of you only candidates has mid- few it well XX features: small, is to shareholders This portfolio. As we where disease later. early, double a those well-defined designed
of Second, readouts a and a just consistent and story XXXX beyond is help But are for right data it the our importantly, path. flow pipeline expansion maybe enables not demonstrate candidates more Arrowhead. on to that
in We our commercialize source way maximize but by intend in patient a commercial clinical making to from transition organization, and are is stage build a way that and this backed We an also wholly-owned access to selectively strategically We and discovery and that clinical and discovery to also a worldwide. capital-conscious. to speed partner out want early and orderly and values engine. company programs, capital a efficient execution, a develop powerful drugs risk, to emerging into manage late-stage
big is in a approach innovation a company. as fashion, us platform this opportunity Arrowhead pharmaceutical for with big step will We phase growing mind. typical and in a This
call the take next since our closer period of look our last a this progress phase this growth. quarter now last preparing during some and for earnings and is Let's how us of at the
of other ANGPTLX to liver mentioned, results reductions shown quality clinical from by reported changes Heart at the virtue targets. of the proteins, in leading APOCX wholly-owned data, scientific in durability single-ascending-dose This power the initial portions remarkable an candidates, ARO-ANGX the in parameters. important for first-in-human the effect These I They and and the American is and dose-dependent X triglycerides back-to-back our and Association we were various and sessions cardiometabolic ARO-APOCX of accomplishment studies. durable impressive As presentations. results of of the demonstrated robust, plenary the
they We patients idea are of ongoing, are give multiple-dose you studies. an And still these portion treating what now while I of we are can in seeing. the
speaks. In when addition, Bruce more will provide he detail a bit
dose dose in started are perspective, around the this X,XXX severe per of after XX% days seeing is, study the astonishing. milligrams triglycerides This and ARO-APOCX. first At of To hypertriglyceridemia. APOCX, a triglycerides, deciliter we one put patients just XX reductions in just to XX-milligram XXX fell circulating with patient with into of quite frankly, this of
this XX of reduction life to with mean reduction type pancreatitis. patients and for milligrams with deciliter. X,XXX would days substantial particularly quality the cohort per We history in the absolute have clinical was this least -- of impacts, fact, of at minus patients expect data in at of In X this
we frequent. We extremely and as hypertriglyceridemia relatively triglyceride plan are with drug talking levels be expect lowering X focused -- months about severe to potentially our to ARO-APOCX patients less hypertriglyceridemia, This normal every to with a severe moving or supports triglyceride rapidly. develop dosing
patients This a believe with chylomicronemia that a rare in that also representing polygenic population tell develop KOLs While hypertriglyceridemia about and to this is FCS, syndrome, is FCS, powerful drug pancreatitis. we patients XX,XXX could this of approximately for patients still we with the history be or treat alone. plan U.S. broadly to more but of indication, effective hundredfold the us potential familial
ARO-ANGX. seeing are ongoing data with the We promising also studies in
goal, around For short saw in ARO-ANGX. XX%, their statins, have reduction already milligrams patients on in per XXX in to seen for than who to circulating a a deciliter, XX% exposure but are triglycerides instance, reach unable reduction greater patients of LDL-cholesterol with triglycerides. in further LDL-cholesterol And we we
is of effect and also insulin evaluating liver still blinded, the sensitivity of fat. the ARO-ANGX on cohorts, One
dosing be As every with months we X expect ARO-APOCX, or to less frequent.
of While we X in inhibitors. could it developing expect shot hypertriglyceridemia, we as symptomatic broader drug-related to we a a indeed, severe of still to are as against and hit this rated against indicate important fellow risk. and even serious be there market drug as as multiple view ARO-ANGX dyslipidemias, potentially statins discontinuations severe rifle view in profound to Because ARO-APOCX medicines cardiovascular it and a ARO-ANGX pathways due we PCSK any trailers and haven't the drug. been reports syndrome metabolic age no impact genetic studies and medicine and have appear where a ARO-APOCX creating powerful or AEs pathologies,
We read XXXX present various scientific conferences as data studies expect out. the at to throughout
data durability specifically. TRiM tolerability. programs We benchmark believe validation broadly achieving hepatocyte-targeted providing These and Arrowhead are clinical for and further platform the activity, is
So speaks predictability and reliable scalability far, animals we with and of to hepatocyte-targeted as translation to have enjoyed we the us into very latest confidence candidates, preclinical consistent move of clinical clinic gives platform. and this This ARO-HSD. our the studies, the human results in
that human hepatitis begin some IRB of to noncarriers. candidate regulatory HSDXXBXX we by CTA the dosing generated deal year. compared begin of December, filed loss unsolicited a will studies. alcoholic to a program, with of for reach happy function report quarter, inbound it data to against human of clinical in provides expect the targeting risk and to XX% has indicate and drug We cirrhosis, is partners. great end I ARO-HSD XX% and testing. we HSDXXBXX to first multiple strong and the this be target have this approval now potential and data cirrhosis possible Published NASH, we that have could the any interest protection This from approximately genetic that a expect reduction In modality mutation to I'm
to expect the what I would talk now to about program. with like ARO-AAT
activate fastest Europe, SEQUOIA this, are share, North and possible America potentially registration. enrolling patients the and which there study, We SEQUOIA the X last some study. data treatment. but That is provides be of the in time path to receive us placebo-controlled is will are before of in it continue any approximately to a pivotal to in that Because years with blinded patient we believe structure to sites
an and months, began treatment. baseline Last AROAATXXXX, open-label dosing XX and with Phase biopsies liver study XX of month, II after months months, months X at we XX
is aspects end to fully data publicly those share the we expect at by data the of by X so the we some biopsy enrolled, and The fall, year. to repeat first first cohort month hope have least of
transform clinical truly as We to discussed in be year progress it earlier, we extensively outside medicine, we believe I we've that RNAi over the As And past, as proof-of-concept the made tissues we months. XXXX past establish see liver. in TRiM-enabled needs the beyond for RNAi hepatocytes. important to for stated applied the
cell IND target well-validated December, a is In an our filed for the RCC. form candidate for first carcinoma. of we HIF-X alpha tumor-targeted cell against ARO-HIFX, renal clear
and get as into other So we The we about excited specifically technology very for than is it ARO-HIFX are solid mean tumors patients. rather delivery to what employing well, RCC. are can designed
and we we achieve types. This undruggable. value that solid of As targets a potentially new rapidly we are mean pipeline for our used in candidates our an variety drug is and important platform may expand focused be study HIF-X that could important numerous multiple on a oncology such, heretofore point. can against establishing against Once additional proof-of-concept, scalable alpha some could It across be a which a inflection proof-of-concept that of is clinical the tumors to clinical silencing RCC with represent model powerful current model. tumor potentially targets, have
believe So we patients we the clearance dosing quarter. early year. I to this hope report clinical happy is from I'm when begin study, to achieve is as then that could we as begin and to this FDA I the proof-of-concept. have question now this Phase answer the
the now to Let's move lung.
some epithelial silencing cells the our As sodium American the filing a North this we focus for inhalation developing treatment on channel, deliver half ARO-ENaC. pulmonary fibrosis. for on candidate. cystic the -- are pulmonary time ENaC via schedule in for of the remain initial Fibrosis on now, on we you Last at to epithelial for with Conference or an quarter, ENaC, ability presented to data know, of first CTA preclinical XXXX We Cystic
There step positive with we a view genotype. could believe due point. has the establishing data to pulmonary important we a system. clinical important humans, of Once COPD, potentially in potentially for broadly, our well-validated as areas be CF As such a CF fibrosis any so animal expansion. and we toxicity data aggressive demonstrating is large value ENaC inflection delivery be ARO-HIFX, proof-of-concept pulmonary to how relationship will we systemic opportunities have potential of as big in are data validation for would target serve a been as with an that translate undruggable pipeline patients it More number asthma, others.
value lot same we we with TRiM of say, believe We with have and our direct creative do are amount everything tremendous platform, integrated clearly take a and a highly the and I of solid Needless lung-directed TRiM work. platforms. and to creating can described will tumor hepatocyte
and have ARO-APOCX; of X CTAs; Phase our data muscle hope meetings months most the of first targeting cells; with existing we during II programs; clinical for X ARO-ANGX file continue up EMA and and XXXX, program Chief next-generation XX Medical clinical senior expanded working instance, a remaining our and undisclosed X across have leaders, to these end For and infrastructure. Martin Dr. to skeletal new Jim Hassard FDA of Dr. Chief as readouts our to ARO-AAT, create we pharma San of Officer. build start with Bradshaw Scientific Chief programs; Officer; Officer; Javier hiring ends, on pre-commercial Toward management seasoned Curt the biotech as Commercial as out to team
joined been as and commercial running confidence already wanted grow. continue areas. campaigns. records joined been and for additions impactful Therapeutics, and co-founded was have from innovative responsible disease Together, NDAs, Hospital Prior he Medical development roles Tollnine, Traversa give Pharmaceuticals with Curt in and Eli These company and large leaders us our held for Abbott medicine. small can have from of to and Prior Development. was University Research, Senior maintain Biopharmaceuticals, he his Biologics, Ligand to INDs, rare he they conjugates that Lilly, that, Buenos discovery, Arrowhead as with Javier track at at programs Ultragenyx, commercial to Aires he We in to develop to proven effective Global novel career internal we we President and us culture physician where of of Amgen Head studies, dozens and launches high-prevalence product that, clinical Solstice immunooncology. clinical after attending antibody beginning a Alder in CEMIC development CovX Laboratories. marketing us Vice
with and Vice BioSciences, Market Senior us joined that, to Jim Schering Amgen and Coherus was from Medivation, where he Access. Prior President of Plough. was he Marketing
make innovative of Directors. deep passion Development Backer at was we Executive with also appointed she know We new De part broad our and Global Head new Board Dr. transactions when a our Janssen, Head of were Marianne Her De patients, President, them. the Development negotiating Global AG. background of a Vice of Executive partnership as independent for finding as in currently Business and hundreds technical great Bayer medicines Director. fit her Business for got a of experience Backer division the Dr. member We Licensing of Pharmaceuticals and to of and of She's Committee
over XXXX, requires financing in we talent capital. made improved cash a had Dr. million. intend our like as quarter after and at XXXX our very impressive company progress on turn to still therapeutics that we course, and our clear we maintain of broadly. that to that quarter I'd position. execution. the lot proceeds we of Arrowhead, on field, in we that view in overview, another with and keep are leader the RNAi addition in runway end, now the We gas Even early Bruce Of last field growth sheet Clearly, call foot Bruce? much going $XXX and Given. to gross the stages With with approximately Toward a to the our for extended balance of for and there's the great to feel Arrowhead
